Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
NCT03801434Phase 2Active, not recruiting
- Sponsor
- Stanford University
- Start
- Nov 2019
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in hypereosinophilic syndrome (HES) and Eosinophilic disorder, sponsored by Stanford University. Primary endpoint: Overall response rate at 3 years. Started Nov 2019; status: active, not recruiting.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)Eosinophilic disorder
Beyond the preview
Go deeper on NCT03801434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801434.